# 1 **Benchmarking CRISPR-BP34 for point-of-care melioidosis detection in LMIC: a**  2 **molecular diagnostics study**

3



- 5 Chomkatekaew<sup>1</sup> Msc; Yaowaret Dokket<sup>1</sup> Bsc, Areeya Faosap<sup>1</sup> Bsc, Gumphol Wongsuwan<sup>1</sup> Msc;
- 6 Vanaporn Wuthiekanun<sup>1</sup> Bsc, Panatda Aramrueung<sup>2</sup> Msc; Phadungkiat Khamnoi<sup>3</sup> Bsc; Hathairat
- 7 Thananchai<sup>4</sup> DPhil; Suwattiya Siriboon<sup>5</sup> MD; Parinya Chamnan<sup>5,6</sup> PhD; Sharon J Peacock<sup>7</sup> PhD;
- 8 Nicholas PJ Day<sup>1,8</sup> DM; Nicholas R Thomson<sup>9</sup> PhD; Chayasith Uttamapinant<sup>10</sup> PhD; Somsakul

9 Pop Wongpalee<sup>4</sup> PhD<sup>\*</sup>; Claire Chewapreecha<sup>1,9,11</sup> PhD<sup>\*</sup>

# 10 **Affiliations:**

- 11 1. Mahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical 12 Medicine, Mahidol University, Bangkok, Thailand
- 13 2. Central Laboratory, Sunpasitthiprasong Regional Hospital, Ubon Ratchathani, Thailand
- 14 3. Diagnostic Laboratory, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand
- 15 4. Department of Microbiology, Faculty of Medicine, Chiangmai University, Chiang Mai, 16 Thailand
- 17 5. Department of Infectious Medicine, Sunpasitthiprasong Regional Hospital, Ubon
- 18 Ratchathani, Thailand
- 19 6. Cardiometabolic Research Group, Department of Social Medicine, Sunpasitthiprasong 20 Regional Hospital, Ubon Ratchathani, Thailand
- 21 7. Department of Medicine, University of Cambridge, UK
- 22 8. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 23 University of Oxford, Oxford, UK
- 24 9. Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton, UK
- 25 10. School of Biomolecular Science and Engineering, Vidyasirimedhi Institute of Science 26 and Technology (VISTEC), Rayong, Thailand
- 27 11. Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol 28 University, Bangkok, Thailand

- 30 \*Indicates equal contribution and corresponding authors: somsakul.w@cmu.ac.th
- 31 (+66(0)924483033) and claire@tropmedres.ac (+66(0)952743357)

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.05.06.23289616;](https://doi.org/10.1101/2023.05.06.23289616) this version posted June 4, 2023. The copyright holder for this preprint

#### 32 **Summary**

#### 33 **Background**

34 Melioidosis is a grossly neglected but often-fatal tropical disease. The disease is named "a great 35 mimicker" after its broad clinical manifestations, which makes disease diagnosis challenging and 36 time-consuming. To improve diagnosis, we developed and evaluated the performance of the 37 CRISPR-Cas12a system called "CRISPR-BP34" to detect *Burkholderia pseudomallei* DNA 38 across clinical specimens from patients suspected to have melioidosis.

#### 39 **Methods**

40 We documented time taken for diagnosis, antibiotics prescribed during the waiting period, and 41 infection outcomes in 875 melioidosis patients treated in a hospital in northeast Thailand 42 between October 2019 and December 2022. In the last six months, we performed CRISPR-BP34 43 detection on clinical specimens (blood, urine, respiratory secretion, pus and other body fluids) 44 collected from 330 patients with suspected melioidosis and compared its performance to the 45 current gold-standard culture-based method. Discordant results were validated by three 46 independent qPCR tests.

#### 47 **Findings**

48 A window of 3-4 days was required for gold-standard culture diagnosis, which resulted in 49 delayed treatment. 199 [22·7%] of 875 patients died prior to diagnosis results while 114 [26·3%] 50 of 433 follow-up cases had been diagnosed, treated, but died within 28 days of admission. A 51 shorter sample-to-diagnosis time of less than 4 hours offered by CRISPR-BP34 technology could 52 lead to faster administration of correct treatment. We demonstrated an improved sensitivity of 53 CRISPR-BP34 (106 [93·0%] of 114 positive cases, 95% CI 86·6 - 96·9) compared to the culture 54 approach (76 [66·7%] of 114 positive cases, 95% CI 57·2 - 75·2); while maintaining similar 55 specificity (209 [96·8%] of 216 negative cases, 95% CI 93·4-98·7) to the culture (216 [100 %] of 56 216 negative cases, 95% CI 98·3-100·0).

# 57 I**nterpretation**

- 58 The sensitivity, specificity, speed, window of clinical intervention, and ease of operation offered
- 59 by the CRISPR-BP34 support its use as a point-of-care diagnostic for melioidosis.
- 60 **Funding**
- 61 Chiang Mai University Thailand and Wellcome Trust UK

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.05.06.23289616;](https://doi.org/10.1101/2023.05.06.23289616) this version posted June 4, 2023. The copyright holder for this preprint

#### 62 **Research in context**

#### 63 **Evidence before this study**

64 Melioidosis is an often-severe infectious disease caused by the bacterium *Burkholderia*  65 *pseudomallei*. It is estimated to affect 165,000 individuals annually worldwide, of which 89,000 66 cases are fatal. The disease diagnosis is challenging due to diverse clinical presentations, low 67 awareness, limited diagnostic options, or even a lack of diagnostic tests. A PubMed search 68 conducted from the database inception to 6 May 2023, using the terms "melioidosis" AND 69 "diagnosis test," yielded 207 results, 40 of which presented clinical evaluations of rapid 70 melioidosis diagnostic tests. Antigen-based diagnostic tests, which detect the presence of *B.*  71 *pseudomallei*, reported high specificity (median = 98·6%, IQR 94·0 - 100·0), but low sensitivity 72 (median = 57·1%, IQR = 44·3 - 82·5). The test sensitivity suffers from the often-low 73 concentration of the bacterial antigens in patients' samples, which can vary by specimen type and 74 stage of infection. Antibody-based diagnostic tests that detect host antibodies against *B.*  75 *pseudomallei* typically exhibit satisfactory specificity (median = 94·5%, IQR = 88·6 - 96·2) but 76 poor sensitivity (median =  $80.2\%$ , IQR =  $71.0 - 88.1$ ). These tests are often impacted by 77 variations in antibody responses to *B. pseudomallei* and the duration required for antibody 78 production. Furthermore, standardisation remains challenging due to the influence of different 79 serum titres on sensitivity and background of the tests. Likewise, quantitative PCR exhibits a 80 high degree of specificity (median  $= 99.8\%$ , IQR  $= 91.6-100.0$ ), but an observed low sensitivity 81 for melioidosis (median  $= 77.1\%$ , IQR  $= 20.8-97.8$ ), which is likely attributed to the genetic 82 heterogeneity of *B. pseudomallei* genomes. Additionally, these studies consistently reported a 83 demand for improved speed and ease of implementation in resource-limited settings where 84 melioidosis is endemic. With the limitations of current diagnostic methods, a culture-confirmed 85 approach with 60% sensitivity, 100% specificity, and a diagnosis time of 2-7 days still stands as 86 the gold standard for melioidosis diagnosis.

#### 87 **Added value of this study**

88 To date, no study has measured the impact of delayed diagnosis on melioidosis. We assessed the 89 number of deaths occurring prior to culture-confirmed diagnosis (22·7%) and those after 90 diagnosis but within 28 days post-admission (26·3%), highlighting the urgent need for prompt 91 action. To address this, we developed the CRISPR-BP34 test, which utilises isothermal 92 amplification of a nucleic acid target followed by site-specific detection using a CRISPR-Cas12a

93 enzyme. We successfully implemented this assay in a resource-limited setting in northeast 94 Thailand, where the disease prevalence is among the highest in the world. The assay achieved a 95 diagnostic sensitivity and specificity of 93·0% and 96·8%, respectively, with a limit of detection 96 ranging from 50-250 cfu/mL. Early diagnosis can be achieved within four hours of patient 97 admission, which is significantly faster than the gold-standard test that typically takes several 98 days. Moreover, the ultrasensitivity of the CRISPR-BP34 assay enabled the detection of low 99 levels of *B. pseudomallei* in hemoculture bottles, which could be missed due to mixed infections, 100 poor aseptic technique, or other causes, leading to undiagnosed melioidosis.

# 101 **Implications of all available evidence**

102 The CRISPR-BP34 assay holds great promise for the management and control of melioidosis. Its

103 minimal setup and shallow learning curve make it well-suited for resource-limited settings.

104 Additionally, its speed and high sensitivity enable early diagnosis and treatment, which are

105 crucial for saving patients' lives.

# 106 **INTRODUCTION**

107 Melioidosis is a neglected tropical disease with a high case-fatality (10-50%) even when  $108$  appropriately treated<sup>1</sup>. The global disease burden expressed in disability-adjusted life-years 109 (DALYs) is 4.64 million, 99% of which is accounted for by years of life lost  $(YLL)^2$ . High 110 mortality may be explained by the disease disproportionately affecting rural populations in low-111 and middle-income countries  $(LMICs)^3$ , many of which have poor socioeconomic conditions and 112 often present to healthcare facilities in a terminal or critical phase of the disease<sup>4</sup>. Melioidosis is 113 caused by *Burkholderia pseudomallei*, an environmental bacterium in soil and water across the 114 tropical regions of Asia Pacific<sup>5</sup>, South<sup>6</sup> and Southeast Asia<sup>7</sup>. However, the disease remains 115 largely underreported due to its non-specific clinical manifestations that can "mimic" several 116 other diseases. A lack of disease awareness in clinics and communities as well as the paucity of 117 diagnostic facilities leads to missed or delayed diagnosis. With early diagnosis and appropriate 118 treatment the mortality rate from melioidosis can be decreased to less than  $10\%$ <sup>5</sup>.

119

120 Clinical specimens from patients with suspected melioidosis are typically screened for the 121 presence of *B. pseudomallei* using microbial culture, which has been the gold standard diagnostic 122 method for the last three decades. This method is imperfect, with a specificity of 100% but a 123 sensitivity of 60%<sup>8</sup>. *B. pseudomallei* grows more slowly in the laboratory compared with other 124 pathogens<sup>9</sup>, which can lead to over-growth by other bacteria or fungi present in the sample as 125 part of a mixed infection and/or contamination. This can result in failure to detect *B.*  126 *pseudomallei*. If cultured successfully, *B. pseudomallei* colonies can be easily misinterpreted as 127 environmental contaminants, and correct identification requires an expert microbiologist. 128 Moreover, a combined time to grow and identify *B. pseudomallei* may take up to 7 days, which 129 inevitably delays the disease diagnosis<sup>8</sup>. Culture-free antigen-based and nucleic acid-based tests 130 such as a lateral flow immunoassay  $(LFD^{10}$ , an immunofluorescence assay  $(FA)^{11}$ , polymerase 131 chain reaction  $(PCR)^{12-14}$ , or 16S rRNA sequencing<sup>15</sup> have been developed for the diagnosis of 132 melioidosis. However, the heterogeneity in bacterial concentrations<sup>16,17</sup> across clinical specimens 133 leads to a limited sensitivity of 58.2% (95% CI, 34.1 – 78.9%) for LFI<sup>18</sup> and 63.8% (45.6 – 134  $-78.7\%$ ) for IFA<sup>18</sup>; whilst tests that offer higher sensitivity require thermal cyclers or sequencing 135 machines<sup>15</sup>, which are rarely available in rural settings.

137 An improved sensitive and specific detection of *B. pseudomallei* DNA in a range of sample types 138 using field-deployable equipment has the potential to improve the diagnosis of melioidosis. This 139 can be achieved by first amplifying DNA of the pathogen using recombinase polymerase 140 amplification (RPA), followed by sequence-specific recognition of clustered regularly 141 interspaced short palindromic repeats (CRISPR)-Cas12a endoribonuclease at the DNA target. 142 This approach has been applied to other bacterial pathogens including *Mycobacterium*  143 *tuberculosis*<sup>19</sup> and has been demonstrated to improve diagnosis and treatment responses. We 144 previously described a robust CRISPR-based detection of genomic DNA of *B. pseudomallei in* 145 *vitro*<sup>20</sup>. Here, we addressed the issues surrounding delayed diagnosis of melioidosis, established 146 a diagnostic protocol for our recently developed CRISPR-Cas12a system (here-after termed 147 CRISPR-BP34)<sup>20</sup>, and determined its diagnostic sensitivity and specificity. Our results showed 148 higher sensitivity and shortened diagnostic time of the CRISPR-BP34 detection compared with 149 the gold standard culture.

150

# 151 **METHODS**

#### 152 **Study design and patients**

153 Two related studies were conducted and reported here. Study 1 quantified the time taken to 154 diagnose melioidosis based on culture and patient outcome, and Study 2 evaluated the diagnostic 155 performance of the CRISPR-BP34 assay (Figure 1).

156

157 Study 1 was a prospective observational cohort study of patients with culture-confirmed 158 melioidosis at Sunpasitthiprasong Hospital, a tertiary care hospital in Ubon Ratchathani, 159 Thailand between October 2019 and December 2022 (Figure 1A, appendix p 3). Study objectives 160 were to assess the disease prevalence, the time taken to reach a diagnosis of melioidosis, the 161 empirical antibiotics prescribed prior to diagnostic confirmation, and patient survival during 28- 162 day follow-up from the admission date. Routine clinical practice was to obtain blood, urine, 163 respiratory secretions and fluid (sputum, tracheal suction, pleural fluid), and other body fluid and 164 tissue as available (pus, limb tissue, and synovial fluid) for culture from patients with suspected 165 melioidosis. All samples were collected according to WHO guidelines<sup>21</sup>. The standard culture 166 methods used for each specimen type are outlined in the appendix (p 5). All patients with 167 culture-confirmed melioidosis were identified through the hospital computer. The length of time

168 between sampling and culture result was recorded for each patient. Cases who remained alive 169 when the culture result become available were visited to obtain written consent to collect clinical 170 information. 875 culture-confirmed melioidosis cases were identified, of whom 433 were alive at 171 the time of culture confirmation and gave written consent to obtain and use clinical information 172 on antibiotic treatment and 28-day outcome (Figure 2). The study received ethical approval from 173 the Sunpasitthiprasong Hospital Ethical Review Board (015/62C) and the Oxford Tropical 174 Research Ethics Committee (OxTREC, 25-19). This study is registered with Thai Clinical Trial 175 Registry (TCTR20190322003).

176

177 Study 2 was a diagnostic evaluation of the sensitivity and specificity of a CRISPR-BP34 178 prototype assay<sup>20</sup> conducted at Sunpasitthiprasong Hospital between May 2022 and December 2022 (Figure 1B). Minimal sample size was determined using the formula  $n = z^2 p(1-p)/d^2$  where 180 "z" is the 95% confidence interval at 1·96; "p" is the prevalence at 0·5; and "d" represents the 181 margin of error at 0·1. At least 96 melioidosis and 96 non-melioidosis patients were required for 182 the CRISPR-BP34 diagnostic test. Specimens were collected from patients with suspected 183 melioidosis (appendix p 4) at the time of hospital presentation for culture identification. 1 mL of 184 leftover sample from the culture was obtained from the hospital microbiology laboratory and 185 stored at -20 °C for CRISPR-BP34 screening. Once the culture results arrived (appendix p 5), a 186 head-to-head CRISPR-BP34 assay (appendix pp 7-9 & 10-16) was performed. In total, the study 187 examined 114 melioidosis and 216 non-melioidosis patients, which were sampled across four 188 different specimen types: blood (41 and 74 samples), respiratory secretions and fluids (52 and 54 189 samples); urine (27 and 71 samples), and other body fluids and tissues (15 and 30 samples) from 190 melioidosis and non-melioidosis patients, respectively. The study received ethical approval from 191 the Ethical Review Board of Sunpasitthiprasong Hospital (029/65C) and received ethical 192 exemption from Chiang Mai University (9190/2565).

193

# 194 **Determining the molecular sensitivity of CRISPR-BP34 assay** *in vitro*

195 To determine the limit of detection of the CRISPR-BP34 assay, we conducted *in vitro* 196 experiments by inoculating genetically modified *Escherichia coli* that harbors a target DNA of 197 the CRISPR-BP34 in its genome (appendix p 6) into blood and urine samples from a single 198 healthy donor at different concentration ranging from 0, 10, 50, 100, 250, 500, 2500 and 5000

199 cfu/mL. Two to five biological replicates were performed for each experiment. CRISPR-BP34 200 detection was performed on blood as described in the appendix (pp 7-8). Blood and urine were 201 selected to represent the most common types of clinical specimens processed from patients with 202 suspected melioidosis. The use of the modified *E. coli* as a surrogate for *B. pseudomallei* was to 203 circumvent laboratory safety requirement.

204

# 205 **Clinical evaluation of CRISPR-BP34 assay**

206 Different types of clinical sample require specific sample preparation due to the variable 207 amounts of target bacterial cells<sup>16</sup>, host cells and inhibitors present in each sample. Further 208 details of how the assay was performed on each sample type is described in the appendix (pp 7- 209 8). For each clinical sample, human cells were first depleted using a simple buffer system to 210 selectively lysed human cells, leaving a pellet of bacterial cells. Bacterial genomic DNA was 211 then extracted from the pellet using either hot alkaline lysis or a spin column, depending on the 212 pellet size. *B. pseudomallei* DNA was amplified in an RPA reaction, and the resulting amplicons 213 were added into a 50-µL CRISPR reaction, comprising of CRISPR RNA (crBP34)<sup>20</sup>, LbCas12a 214 protein and FAM-biotin probes. This reaction was incubated at 37 °C for 60 minutes, after which 215 a HybriDetect lateral flow dipstick (TwistDx, UK) was directly immersed into the reaction and 216 allowed to develop for 5 minutes before reading by eye. A positive result was defined as the 217 appearance of an upper band (anti-IgG) on the dipstick. The assay was performed in a batch of 218 10 samples with each batch comprising of culture positive and negative samples to avoid batch 219 effect. For all batches, *B. pseudomallei* positive sample and distilled water were used as positive 220 and negative controls, respectively. The sample-to-result time was recorded. The CRISPR-BP34 221 results were interpreted by three different readers who were blinded to the patient disease status 222 and culture results.

223

224 Not every sample cultured from a melioidosis patient yields positive result, a scenario driven by 225 different local concentration of *B. pseudomallei*. Discordant results between culture and the 226 CRISPR assay were tested by quantitative PCR (qPCR) using three primer sets listed in the 227 appendix (pp 9, 19-20). Given a large discrepancy in reported diagnostic sensitivity of PCR 228 primers<sup>18</sup> and a high sequence diversity of *B. pseudomallei*, the use of primer combinations

229 ensured an increased coverage of the detection. The qPCR cycle threshold (ct) values were 230 recorded and used as a proxy for bacterial loads.

231

# 232 **Statistical analysis**

233 All numerical data was summarised using medians, interquartile ranges (IQR), and proportion. 234 For comparison with non-parametric distribution, Wilcoxon signed-rank tests were used with 235 Benjamini-Hochberg correction for multiple testing. The culture and CRISPR-BP34 results from 236 the same specimen were compared against the patient's disease status. Sensitivity and specificity 237 were defined as TP/  $(TP + FN)$  and TN/  $(TN + FP)$ , respectively. "TP" and "FN" represent the 238 number of cases that tested positive and negative in the disease group, respectively. "TN" and 239 "FP" are the number of cases that tested negative and positive in the non-disease group, 240 respectively. The sensitivity and specificity were separately calculated for culture and CRISPR 241 by sample type (grouped into four categories: blood; urine; respiratory secretion; and pus, tissue 242 and other body fluid), and by total specimens. For a patient who had multiple samples taken, 243 only the earliest sample was included for sensitivity and specificity calculations. The exact 95% 244 confidence interval was estimated using Clopper-Pearson Binomial assumption<sup>30</sup>.

245

#### 246 **RESULTS**

# 247 **Time to diagnosis, empirical antibiotic treatment, and outcomes**

248 Of 875 culture-confirmed melioidosis patients admitted or referred to Sunpasitthiprasong 249 Hospital during October 2019 to December 2022, 199 died before the culture results arrived 250 (Figure 1A). Among 433 patients who survived to culture results and consented to participate in 251 our study, 114 patients died within 28 days after first presentation to Sunpasitthiprasong hospital. 252 The minimum fatality of 35·8% based on the combined data is consistent with 35% mortality 253 reported in Thailand<sup>22</sup>. A relatively high fatality reported in this setting could be attributed to 254 socioeconomic disparity<sup>2</sup> which impacted mostly agricultural workers  $(272 \mid 62.8\%)$  of 433 255 patients) who lived on average 65 km (IQR  $40 - 100$  km) from the culture-confirmed diagnosis 256 facility (Table 1). Melioidosis patients displayed diverse clinical manifestations with persistent 257 fever being the most common symptom (Table 1, appendix p 18. Patients experienced symptoms 258 for a median of seven days (IQR 3 -14 days) before seeking medical care at the local or central 259 health-care centres, which subsequently referred them to Sunpasitthiprasong hospital within one

260 day (IQR  $0 - 4$  days). Multiple samples were collected from patients for culture diagnosis upon 261 first admitted or referred, and during their stay at Sunpasitthiprasong hospital as clinically 262 indicated. The median duration between the first sample collection and the first positive culture 263 result was four days (IQR 3 - 5 days), at which point melioidosis diagnosis was confirmed. 264 Notably, the time from symptom onset to diagnosis averaged 16 days (IQR  $9 - 27$  days), 265 although this differed significantly between patients who died (12 days, IOR  $7 - 19$  days) and 266 those who survived (18 days, IQR 10 – 31 days, Wilcoxon test p-value =  $5.62 \times 10^{-5}$ ), 267 underscoring the need for prompt clinical intervention to avert fatal outcomes.

268

269 In Thailand, patients suspected of having melioidosis are recommended to receive empiric 270 treatment with intravenous ceftazidime or a carbapenem antibiotics, such as meropenem or 271 imipenem, for initial intensive monotherapy<sup>23</sup>. Antibiotic administration data was available for 272 433 patients of which 49 (11·3%) and 54 (12·5%) respectively received ceftazidime or a 273 carbapenem monotherapy upon their first presentation to Sunpasitthiprasong hospital (Figure 2A, 274 Table 1). The remainder received other treatments including a monotherapy or combinations of 275 antibiotics known to be ineffective in treating melioidosis such as lincosamides<sup>24</sup>, 276 macrolides<sup>24,25</sup>, penicillin<sup>25</sup> and first- and second-generation cephalosporin<sup>24,26</sup>, and ineffective 277 third-generation cephalosporins such as ceftriaxone<sup>27</sup>; an inevitable practice to cover the broad 278 spectrum of infection when the causative agents were unknown (Figure 2B & C). A lower 279 mortality (5 [10·2%] of 49) was observed in patients who received ceftazidime monotherapy than 280 in patients who received other types of treatments (109 [28·5%] of 382; Fisher's exact p-value 281  $-5.42 \times 10^{-3}$ , Table 1). To increase the use of ceftazidime monotherapy at first presentation from 282 11·3% to 100%, a more rapid diagnosis will be necessary.

283

# 284 Clinical evaluation of the CRISPR-BP34 assay<br>285 We developed the CRISPR-BP34 assay to detec

285 We developed the CRISPR-BP34 assay to detect *B. pseudomallei* DNA, which demonstrated 286 high sensitivity and specificity *in vitro*<sup>20</sup>. We tested the limit of detection of the CRISPR-BP34 287 by spiking blood and urine samples and found it to be 250 cfu/mL and 50 cfu/mL, respectively 288 (Figure 3A & B). To determine whether CRISPR-BP34 test is sufficiently sensitive to detect the 289 bacterium across various clinical samples, we enumerated the numbers of *B. pseudomallei*  290 recovered from different specimen types using both new experiments and previous datasets<sup>16,17</sup>

291 (Figure 3C). Our results showed that the number of *B. pseudomallei* detected in most common 292 specimens such as urine (median =  $2.6 \times 10^4$  cfu/mL, sputum (median =  $8.8 \times 10^7$  cfu/mL), pus 293 and other body fluids (median =  $5.4 \times 10^7$  cfu/mL) were greater than the CRISPR-BP34 limit of 294 detection. Since direct blood samples had a lower *B. pseudomallei* concentration (median = 1·5 295 cfu/mL) than the limit of detection, we substituted direct blood samples with hemoculture 296 positive samples (median = 7.3 x  $10^7$  cfu/mL) to ensure sufficient bacterial concentration. 297 Hemoculture positive samples are blood samples that have been incubated in a culture medium 298 to allow the bacterium to grow, but at this point, the bacterium's identity remained unknown 299 (Figure 3D).

300

301 We tested the hypothesis that CRISPR-BP34 assay would be more sensitive and faster than 302 culture-confirmed approach in clinical samples collected from 114 melioidosis and 216 non-303 melioidosis patients. Of these, 20 melioidosis and 12 non-melioidosis patients had samples 304 collected across multiple specimen types (Figure 4A), while 94 melioidosis and 204 non-305 melioidosis patients had a single sample type collected (Figure 4B). Using first sample available 306 from each patient, we estimated the overall diagnostic sensitivity and specificity of both 307 methods. Our findings showed an overall sensitivity of CRISPR-BP34 of 93·0% (106 of 114 308 samples, 95% CI 86·6 – 96·9), higher than the sensitivity of culture at 66·7% (76 of 114 samples, 309 95% CI 57·2 - 75·2) (Figure 4C, Table 2). The overall specificity of the CRISPR-BP34 was 310 96·8% (209 of 216 samples, 95% CI 93·4 - 98·7), compared to 100% (216 of 216 samples, 95% 311 CI 98·3 - 100) for culture (Figure 4D, Table 2). Sensitivity of CRISPR-BP34 versus culture for 312 individual sample types was generally higher for CRISPR-BP34, as follows: hemoculture at 313 100% (41 of 41 samples) vs 58·5% (24 of 41 samples); urine at 70·4% (19 of 27 samples) vs 314 51·9% (14 of 27 samples); respiratory secretions and fluids at 94·2% (49 of 52 samples) vs 315 84·6% (44 of 52 samples); and other body fluids and tissue at 100% (15 of 15 samples) vs 316 73·3% (11 of 15 samples) in CRISPR-BP34 (Figure 4C and Table 2). Specificity of CRISPR-317 BP34 versus culture for individual sample types was equivalent or slightly lower for CRISPR-318 BP34, as follows: hemoculture at 94·6% (70 of 74 samples) vs 100% (74 of 74 samples); urine at 319 98·6% (70 of 71 samples) vs 100% (71 of 71 samples); respiratory secretions and fluids at 98·2% 320 (53 of 54 samples) vs 100% (54 of 54 samples); and other body fluid and tissue at 98·67% (29 of

321 30 samples) vs 100% (30 of 30 samples) in CRISPR-BP34 and culture assay, respectively 322 (Figure 4D and Table 2).

323

324 In addition, the CRISPR-BP34 assay provided faster results and significantly reduced the 325 turnaround time for all sample types compared to culture approach (Figure 5A, Wilcoxon test p-326 value  $\lt 2.2 \times 10^{-16}$  for all sample types). For culture positive samples, the median sample-to-327 result time was 2.5 days (IQR  $1.8 - 3.3$  days) for hemoculture, and 3.9 days (IQR  $3.7 - 4.1$  days) 328 for urine, respiratory secretion and fluids, as well as other body fluids and tissues. In contrast, the 329 average sample-to-result time for the positive CRISPR-BP34 assay was 1·1 days (IQR 0·7 – 1·5 330 days) for hemoculture, 2.3 hours (IQR  $2.3 - 2.4$  hours) for urine, and 3.3 hours (IQR  $3.1 - 3.4$ 331 hours) for respiratory secretion, and fluids, as well as other body fluids and tissues.

332

# 333 **Potential use case**

334 20 of 114 melioidosis patients had multiple sample types, as well as multiple numbers of samples 335 per type collected over time (Figure 4A, Figure 5), enabling investigation of how each patient 336 was diagnosed and treated in the real world. Early specimens were collected on the first or within 337 a few days of admission or referral to aid disease diagnosis, while late specimens were taken at 338 3-, 5- or 7-days intervals following antibiotic prescription to assess response to the treatment. A 339 proportion of early specimens taken from patients who were later confirmed to have melioidosis 340 were culture negative. This could be either attributed to the concentration of *B. pseudomallei* 341 being lower than the culture limit of detection, or contamination of the samples with other fast-342 growing bacterial species (Figure 5B to D). One striking example was a hemoculture bottle from 343 a melioidosis case presented in Figure 5C, which was contaminated with coagulase-negative 344 staphylococci, a skin commensal. The CRISPR-BP34 assay, however, reported *B. pseudomallei*  345 positive from this contaminated blood bottle, consistent with subsequent qPCR experiments 346 confirming the presence of *B. pseudomallei* DNA and with patient's final diagnosis. We 347 observed a high cycle threshold (ct) score of *B. pseudomallei* in the contaminated hemoculture 348 bottle and other contaminated samples (median = 32·3, IQR 30·5 - 35·9), compared to average ct 349 values detected in *B. pseudomallei* positive hemoculture (median = 14·0, IQR 13·4 - 14·9, 350 appendix p 17). This likely indicates that the *B. pseudomallei* population was outcompeted by 351 contaminant species. Cross-contamination incidents like this are not uncommon in laboratories

352 with limited resources such as in rural Thailand which could result in an underestimation of the 353 true incidence of melioidosis<sup>28</sup>. Regardless, for all cases being followed, CRISPR-BP34 provided 354 earlier identification of *B. pseudomallei* than the culture method (Figure 5B to D).

355

#### 356 **DISCUSSION**

357 The first part of our study documented the time taken from first melioidosis symptom-to-358 diagnosis, the empirical treatment patients received during diagnosis uncertainty, and death that 359 occurred prior or after the arrival of culture-confirmed diagnosis result. We noted that many 360 severely ill patients died before we could reach them, thereby introducing survival bias in our 361 study. Nevertheless, our findings echo the problems of delayed disease diagnosis, and imperfect 362 treatment during diagnosis uncertainty, which may separately, or collectively contribute to death. 363 To improve the appropriate and timeous initiation of melioidosis treatment, we developed an 364 easy to implement point-of-care CRISPR-BP34 assay (appendix pp 7-16), tested the sample-type 365 specific protocols (Figure 3D), and evaluated the test performance (Figure 4) in the second part 366 of our study.

367

368 To our knowledge, a lower limit of detection at the range of 50 – 250 cfu/mL is the highest 369 among reported melioidosis rapid diagnosis tests without requiring extensive equipment such as 370 a qPCR machine or a UV microscope. For common clinical specimens with high bacterial loads  $371$  (over  $10<sup>3</sup>$  cfu/mL) such as hemoculture samples, genitourinary fluids, respiratory secretions, and 372 pus and other body fluids; CRISPR-BP34 could be used on DNA extracted from these direct 373 samples. This resulted in high level of sensitivity of the CRISPR-BP34 test of 93·0% compared 374 to 66·7% sensitivity for overall samples of culture approach (Figure 4C). Although CRISPR-375 BP34 could detect the presence of *B. pseudomallei* at the concentration as low as 50 cfu/mL, the 376 miniscule volume of specimens utilised by the CRISPR approach means that the test can be 377 skewed by inaccurate pipetting or handling errors. Thus, for direct blood samples, we 378 recommend using CRISPR-BP34 on DNA extracted from hemoculture (enriched media) instead 379 of direct blood samples to maintain high sensitivity.

380

381 We also observed a slight drop in the CRISPR test specificity being 96·8% compared to 100% 382 specificity of culture approach across all sample types (Figure 4D). Some of the "false" positives

383 could be "true" but "missed" diagnosis cases as result of current imperfect diagnosis techniques 384 including culture-confirmed approach<sup>8</sup> and  $qPCR^{18}$  with suboptimal primers. Some "false" 385 positives may arise when high copy numbers of genetic materials or RPA amplicons were mixed 386 or handled in a confined bench setting, which is sometimes unavoidable in crowded space of 387 resource-limited laboratories. Alternatively, the CRISPR-BP34 complex may mistakenly target 388 other DNA sequences, resulting in false positives. However, the latter is likely mitigated by the 389 double-layered specificity provided by RPA primers and CRISPR RNA; each of which were 390 carefully designed using the genomic database of over  $40,000$  bacterial and human  $DNA^{20}$ . To 391 ensure robust test, suggestions to minimise the DNA cross-contamination which could generate 392 false positives were fully documented in the appendix (p 9).

393

394 In summary, the CRISPR-BP34 test has exhibited higher sensitivity and comparable specificity 395 to the gold standard culture-confirmed method, with more rapid detection capabilities across 396 various types of clinical specimens. Our findings provide evidence to support the use of the 397 CRISPR-BP34 test as a point-of-care diagnostic tool. Its implementation could lead to prompt 398 initiation of lifesaving treatment (Figure 5B to E), with use cases discussed and positively 399 received by Ministry of Public Health Thailand and regional health authorities<sup>29</sup>.

# 400 **Contributors**

401 CChe and SPW conceived the study and secured funding. PC, SS, CU, HT, CChe and SPW, 402 designed the study. SP, PB, KA, YD, AF, GW, PA, PK, VW, and CCho were involved in study 403 implementation under CChe and SPW supervision. CChe and SPW did the analysis. CChe, 404 SPW, PC, SJP, NPJD, NRT, and CU interpreted the data. CChe and SPW wrote the first draft. 405 All authors read and approved the manuscript.

406

#### 407 **Data sharing**

408 Deidentified participant data that underlie the results reported in the article will be made 409 available upon request. Proposals should be directed to the corresponding author, 410 claire@tropmedres.ac. Proposals will be reviewed and approved by the sponsor on the basis of 411 compliance with the informed consent and scientific merit.

412

#### 413 **Acknowledgements**

414 SPW was funded by TSRI Fundamental Fund 2022, Chiang Mai University (grant number 415 65A104000009) and Faculty of Medicine Research Fund, Chiang Mai University (grant number 416 MIC-2562-06372). CCho was funded by Wellcome International Master Fellowship 417 (221418/Z/20/Z). CChe was funded by Wellcome International Intermediate Fellowship 418 (216457/Z/19/Z) and Sanger International Fellowship. This research was funded in whole, or in 419 part, by the Wellcome Trust. For the purpose of Open Access, the author has applied a CC BY 420 public copyright licence to any Author Accepted Manuscript version arising from this 421 submission.

422

### 423 **Role of the funding source**

424 The funders of the study had no role in study design, data collection, data analysis, data 425 interpretation, or writing of the report.

#### 426 **Figure legends**

427 **Figure 1: Study design: A** summarises the mortality of melioidosis patients who were admitted 428 or referred to Sunpasitthiprasong Hospital between October 2019 and December 2022. All cases 429 were identified by culture-confirmed diagnosis, which commonly arrived on day 4. A substantial 430 number of patients died prior to the arrival of the gold-standard test result. **B** presents our case-431 control study to evaluate the use of CRISPR-BP34 as an alternative rapid diagnostic test. Here, 432 specimens were frozen upon arrival to enable subsequent screening with the CRISPR-BP34 test 433 and head-to-head comparison with culture method.

434

435 **Figure 2: Burden of delayed diagnosis on melioidosis treatments and outcomes: A** an UpSet 436 plot summarises the antibiotic prescription when patients were first presented to 437 Sunpasitthiprasong either as a monotherapy or combination therapy. **B** a histogram presents the 438 number of patients who remained undiagnosed at a daily interval following their first 439 presentation or referral to Sunpasitthiprasong Hospital during October 2019 to December 2022. 440 Black arrow denotes the date when a culture-confirmed melioidosis result was available for most 441 patients. **C** summarises choices of antibiotics being prescribed to patients who remained 442 undiagnosed for melioidosis each day following their admission or referral date. Prescription of 443 ceftazidime or carbapenem drugs either as monotherapy or combination therapy are highlighted 444 in blue, with black arrow marking first day presentation.

445

# 446 **Figure 3: Limit of detection of the CRISPR-BP34 assay and its proposed diagnostic**  447 **pipeline**

448 **A** and **B** present the limit of the CRISPR-BP34 test detection in blood and urine samples which 449 are the two most common specimens, respectively. The dipsticks were shown as two biological 450 replicates with LOD of urine (50 cfu/mL) and blood (250 cfu/mL). **C** summarises the number of 451 *Burkholderia pseudomallei* that can be recovered from different type of specimens. Green bar 452 indicates the range of limit of detection of the CRISPR test. **D** presents an overview of CRISPR-453 BP34 diagnosis based on clinical samples including blood, genitourinary fluid, respiratory 454 secretion, pus and other body fluid that were routinely collected from patients suspected of 455 melioidosis. Bacterial pathogen in blood is typically enriched for growth to the detectable 456 threshold (250 cfu/mL) through hemoculture process.

#### 457

### 458 **Figure 4 Sensitivity and specificity of the culture and the CRISPR approaches**

459 **A** present combined panels of diagnostic results from 32 patients with multiple specimen types. 460 Top to bottom panels summarise results from hemoculture, genitourinary fluid, respiratory 461 secretion, and pus or other body fluids, respectively. For patients with multiple samples per each 462 sample type, only the first sample was presented. Rows in each panel display results from 463 different diagnostic tests including the gold-standard culture, IFA, latex agglutination, and the 464 CRISPR-BP34 test (top to bottom). Each column corresponds to data from each patient with 465 disease status marked as melioidosis (black) or non-melioidosis (grey). **B** summarises findings 466 from 298 patients with single specimen type with results from hemoculture, genitourinary fluid, 467 respiratory secretion and pus or other body fluids presented in the same order as in (**A**). **C** and **D** 468 compare the sensitivity and specificity of the gold-standard culture and the CRISPR-BP34 469 approach, respectively. Dots indicate the actual sensitivity or specificity values while the 95% 470 confidence interval are represented by dotted line (culture) and solid line (CRISPR-BP34).

471

472 **Figure 5 Time taken for the culture and the CRISPR-BP34 approaches, and case examples**  473 **A** illustrates the diagnostic time required for the culture and the CRISPR approaches on the log 474 10 scale. **B** to **E** highlighted selected cases (4 of 20 melioidosis cases) where both multiple 475 sample types and multiple specimens per sample type were available (vertical axis). The 476 horizontal axis represents time in days from the date of admission or referral to 477 Sunpasitthiprasong hospital. Circles mark the dates when samples were taken, while rectangles 478 and triangles present the time when the culture-confirmed results and the CRISPR-BP34 results 479 arrived, respectively. For both culture- and CRISPR-BP34 approaches; black denotes negative 480 result, grey highlights detection of other bacterial species than *B. pseudomallei*, while pink 481 (hemoculture), orange (urine), purple (respiratory secretion) and blue (pus, tissue, and other body 482 fluids) present *B. pseudomallei* positive result from each sample type.

#### 483 **Table 1 Demographic of melioidosis patients admitted or referred to Sunpasitthiprasong hospital and**

# 484 **survived to culture results during October 2019 to December 2022**

# 485 Significant terms following Benjamini-Hochberg correction for multiple testing were marked with asterisks



diagnosis\* (10·0 - 31·0)

#### **Antibiotics prescription on first presentation to Sunpasitthiprasong**: counts (%)

#### **A group of recommended empirical treatment**



#### **Other antibiotics prescribed on first presentation**





# 488 **Table 2 Clinical sensitivity and specificity of culture and CRISPR-based methods.**

# 490 **References**

- 491 1 Wiersinga WJ, Virk HS, Torres AG, *et al.* Melioidosis. *Nat Rev Dis Primer* 2018; **4**: 17107.
- 492 2 Birnie E, Virk HS, Savelkoel J, *et al.* Global burden of melioidosis in 2015: a systematic review and data 493 synthesis. *Lancet Infect Dis* 2019; **19**: 892–902.
- 494 3 Limmathurotsakul D, Golding N, Dance DAB, *et al.* Predicted global distribution of *Burkholderia pseudomallei*  and burden of melioidosis. *Nat Microbiol* 2016; **1**: 15008.
- 496 4 Savelkoel J, Dance DAB, Currie BJ, Limmathurotsakul D, Wiersinga WJ. A call to action: time to recognise<br>497 melioidosis as a neglected tropical disease. *Lancet Infect Dis* 2022; 22: e176–82. 497 melioidosis as a neglected tropical disease. *Lancet Infect Dis* 2022; **22**: e176–82.
- 498 5 Currie BJ, Mayo M, Ward LM, *et al.* The Darwin Prospective Melioidosis Study: a 30-year prospective, 499 observational investigation. *Lancet Infect Dis* 2021; **21**: 1737–46.
- 500 6 Mohapatra PR, Mishra B. Burden of melioidosis in India and South Asia: Challenges and ways forward. *Lancet*  501 *Reg Health - Southeast Asia* 2022; **2**: 100004.
- 502 7 Chantratita N, Phunpang R, Yarasai A, *et al.* Characteristics and one year outcomes of melioidosis patients in 503 Northeastern Thailand: A prospective, multicenter cohort study. *Lancet Reg Health Southeast Asia* 503 Northeastern Thailand: A prospective, multicenter cohort study. *Lancet Reg Health - Southeast Asia* 2023; **9**: 100118.
- 505 8 Limmathurotsakul D, Jamsen K, Arayawichanont A, *et al.* Defining the True Sensitivity of Culture for the Diagnosis of Melioidosis Using Bayesian Latent Class Models. *PLoS ONE* 2010; 5: e12485. 506 Diagnosis of Melioidosis Using Bayesian Latent Class Models. *PLoS ONE* 2010; **5**: e12485.
- 507 9 Peeters M, Ombelet S, Chung P, *et al.* Slow growth of *Burkholderia pseudomallei* compared to other pathogens in an adapted blood culture system in Phnom Penh, Cambodia. *J Med Microbiol* 2019; **68**: 1159–66. 508 an adapted blood culture system in Phnom Penh, Cambodia. *J Med Microbiol* 2019; **68**: 1159–66.
- 509 10 Houghton RL, Reed DE, Hubbard MA, *et al.* Development of a Prototype Lateral Flow Immunoassay (LFI)<br>510 for the Rapid Diagnosis of Melioidosis. *PLoS Negl Trop Dis* 2014; 8: e2727. 510 for the Rapid Diagnosis of Melioidosis. *PLoS Negl Trop Dis* 2014; **8**: e2727.
- 511 11 Tandhavanant S, Wongsuvan G, Wuthiekanun V, *et al.* Monoclonal Antibody-Based Immunofluorescence<br>512 Microscopy for the Rapid Identification of *Burkholderia pseudomallei* in Clinical Specimens. Am J Trop Med Hyg 512 Microscopy for the Rapid Identification of *Burkholderia pseudomallei* in Clinical Specimens. *Am J Trop Med Hyg* 513 2013; **89**: 165–8.
- 514 12 Lowe W, March JK, Bunnell AJ, O'Neill KL, Robison RA. PCR-based Methodologies Used to Detect and 515 Differentiate the *Burkholderia pseudomallei* complex: *B. pseudomallei*, *B. mallei*, and *B. thailandensis. Curr* 515 Differentiate the *Burkholderia pseudomallei* complex: *B. pseudomallei*, *B. mallei*, and *B. thailandensis*. *Curr*  516 *Issues Mol Biol* 2014; **16**: 23–54.
- 517 13 Price EP, Dale JL, Cook JM, *et al.* Development and Validation of *Burkholderia pseudomallei*-Specific 518 Real-Time PCR Assays for Clinical, Environmental or Forensic Detection Applications. *PLoS ONE* 2012; **7**: e37723.
- 520 14 Novak RT, Glass MB, Gee JE, *et al.* Development and Evaluation of a Real-Time PCR Assay Targeting<br>521 the Type III Secretion System of *Burkholderia pseudomallei. J Clin Microbiol* 2006; 44: 85–90. 521 the Type III Secretion System of *Burkholderia pseudomallei*. *J Clin Microbiol* 2006; **44**: 85–90.
- 522 15 Gee JE, Sacchi CT, Glass MB, *et al.* Use of 16S rRNA Gene Sequencing for Rapid Identification and 523 Differentiation of *Burkholderia pseudomallei* and *B. mallei. J Clin Microbiol* 2003; 41: 4647–54. 523 Differentiation of *Burkholderia pseudomallei* and *B. mallei*. *J Clin Microbiol* 2003; **41**: 4647–54.
- 524 16 Wongsuvan G, Limmathurotsakul D, Wannapasni S, Chierakul W, Teerawattanasook N, Wuthiekanun V.<br>525 Lack of correlation of *Burkholderia pseudomallei* quantities in blood, urine, sputum and pus. Southeast Asian J 525 Lack of correlation of *Burkholderia pseudomallei* quantities in blood, urine, sputum and pus. *Southeast Asian J*  526 *Trop Med Public Health* 2009; **40**: 781–4.
- 527 17 Wuthiekanun V, Limmathurotsakul D, Wongsuvan G, *et al.* Quantitation of *B. Pseudomallei* in clinical 528 samples. *Am J Trop Med Hyg* 2007; **77**: 812–3.

- 529 18 Fairley L, Smith S, Maisrikrod S, Henning L. Systematic review and meta-analysis of diagnostic tests for<br>530 diagnosis of melioidosis. Acta Trop 2021; 214: 105784. 530 diagnosis of melioidosis. *Acta Trop* 2021; **214**: 105784.
- 531 19 Huang Z, LaCourse SM, Kay AW, *et al.* CRISPR detection of circulating cell-free *Mycobacterium*  532 *tuberculosis* DNA in adults and children, including children with HIV: a molecular diagnostics study. *Lancet*  533 *Microbe* 2022; **3**: e482–92.
- 534 20 Wongpalee SP, Thananchai H, Chewapreecha C, *et al.* Highly specific and sensitive detection of 535 *Burkholderia pseudomallei* genomic DNA by CRISPR-Cas12a. *PLoS Negl Trop Dis* 2022; 16: e0010659 535 *Burkholderia pseudomallei* genomic DNA by CRISPR-Cas12a. *PLoS Negl Trop Dis* 2022; **16**: e0010659.
- 536 21 WHO. Guidelines for the collection of clinical specimens during field investigation of outbreaks. 2000.<br>537 https://apps.who.int/iris/handle/10665/66348. https://apps.who.int/iris/handle/10665/66348.
- 538 22 Hinjoy S, Hantrakun V, Kongyu S, *et al.* Melioidosis in Thailand: Present and Future. *Trop Med Infect Dis* 539 2018; **3**: 38.
- 540 23 Dance D. Treatment and prophylaxis of melioidosis. *Int J Antimicrob Agents* 2014; **43**: 310–8.
- 541 24 Karunakaran R, Puthucheary SD. *Burkholderia pseudomallei*: In vitro susceptibility to some new and old 542 antimicrobials. *Scand J Infect Dis* 2007; **39**: 858–61.
- 543 25 Hii SYF, Tandhavanant S, Phunpang R, *et al.* Antibiotic Susceptibility of Clinical *Burkholderia*  544 *pseudomallei* Isolates in Northeast Thailand from 2015 to 2018 and the Genomic Characterization of β -Lactam-545 Resistant Isolates. *Antimicrob Agents Chemother* 2021; **65**: e02230-20.
- 546 26 Jenney AWJ, Lum G, Fisher DA, Currie BJ. Antibiotic susceptibility of *Burkholderia pseudomallei* from 547 tropical northern Australia and implications for therapy of melioidosis. *Int J Antimicrob Agents* 2001; **17**: 109–13.
- 548 27 Chaowagul W, Simpson AJ, Suputtamongkol Y, White NJ. Empirical cephalosporin treatment of melioidosis. Clin Infect Dis Off Publ Infect Dis Soc Am 1999; 28: 1328. 549 melioidosis. *Clin Infect Dis Off Publ Infect Dis Soc Am* 1999; **28**: 1328.
- 550 28 Rhodes J, Jorakate P, Makprasert S, *et al.* Population-based bloodstream infection surveillance in rural 551 Thailand, 2007–2014. *BMC Public Health* 2019; **19**: 521.
- 552 29 An academic meeting to reduce high mortality from melioidosis in the 10th Public Health Region,<br>553 Thailand, 2023: published online March 2. 553 Thailand. 2023; published online March 2.

**Figure 1** 

A

875 melioidosis cases admitted or referred to Sunpasitthiprasong Hospital (day 0) between October 2019 - December 2022



Figure 2

 $200$ 



the hospital



**CRISPR-cas limit of detection in complex samples** 

Number of bacterial cells recovered from each specimen type

 $\mathbf{C}$ 



Alternative CRISPR-cas12a diagnosis scheme for patient with suspected melioidosis D



# Figure 4

# A Patients with multiple specimen types (index 1-32)

B Patients with single specimen type (index 33 - 330)



# Figure 5



Date from patient admission (days)